GLP-1 receptor agonist + amylin analog combination

CagriSema Side Effects: Complete Guide

CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist). This combination targets multiple appetite regulation pathways for potentially greater weight loss.

Dosage Information

Forms:

injection (weekly)

Common dosages:

2.4 mg semaglutide + 2.4 mg cagrilintide weekly (trial dose)

Side Effects Overview

CagriSema can cause a range of side effects. Most are mild to moderate and improve as your body adjusts to the medication. Below is a complete list organized by severity.

Moderate (Manageable with Strategies)

Constipation and Digestive Slowdown

Affects 60-70% of users at some point during treatment

Fatigue and Low Energy

Affects 15-30% of users, particularly in the first 1-3 months

Vomiting and Severe Nausea

Affects 5-15% of users, more common with higher doses

Mild (Common, Usually Temporary)

Nausea and Upset Stomach

Affects 20-44% of users, especially during the first few weeks or after dose increases

Headaches

Affects 10-20% of users, especially in the first few weeks

Diarrhea and Loose Stools

Affects 10-20% of users

Important Note

This information is for educational purposes only and does not replace professional medical advice. Always consult your healthcare provider about side effects and treatment decisions. If you experience severe symptoms, seek immediate medical attention.